Summary
Global Markets Direct’s, ‘Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Review, H1 2016’, provides an overview of the Vaginal Atrophy (Atrophic Vaginitis) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vaginal Atrophy (Atrophic Vaginitis) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Vaginal Atrophy (Atrophic Vaginitis)
- The report reviews pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Vaginal Atrophy (Atrophic Vaginitis) therapeutics and enlists all their major and minor projects
- The report assesses Vaginal Atrophy (Atrophic Vaginitis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Vaginal Atrophy (Atrophic Vaginitis)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Vaginal Atrophy (Atrophic Vaginitis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Vaginal Atrophy (Atrophic Vaginitis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
EndoCeutics, Inc.
Foamix Pharmaceuticals Ltd.
Ligand Pharmaceuticals, Inc.
Mithra Pharmaceuticals S.A.
PEPTONIC medical AB
TherapeuticsMD, Inc.
'
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Vaginal Atrophy (Atrophic Vaginitis) Overview 6
Therapeutics Development 7
Pipeline Products for Vaginal Atrophy (Atrophic Vaginitis) - Overview 7
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics under Development by Companies 8
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline Products Glance 9
Late Stage Products 9
Clinical Stage Products 10
Early Stage Products 11
Vaginal Atrophy (Atrophic Vaginitis) - Products under Development by Companies 12
Vaginal Atrophy (Atrophic Vaginitis) - Companies Involved in Therapeutics Development 13
EndoCeutics, Inc. 13
Foamix Pharmaceuticals Ltd. 14
Ligand Pharmaceuticals, Inc. 15
Mithra Pharmaceuticals S.A. 16
PEPTONIC medical AB 17
TherapeuticsMD, Inc. 18
Vaginal Atrophy (Atrophic Vaginitis) - Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Target 20
Assessment by Mechanism of Action 22
Assessment by Route of Administration 24
Assessment by Molecule Type 26
Drug Profiles 28
Estetrol - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
estradiol hemihydrate - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
lasofoxifene tartrate - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
oxytocin - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
prasterone - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
TX-004HR - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Vaginal Atrophy (Atrophic Vaginitis) - Recent Pipeline Updates 39
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects 44
Vaginal Atrophy (Atrophic Vaginitis) - Product Development Milestones 45
Featured News & Press Releases 45
May 03, 2016: Sermonix Pharmaceuticals Announces Dr. Anthony H. Wild as Board Chairman and Investor 45
Apr 02, 2016: TherapeuticsMD Presents Detailed Results from Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy at ENDO 2016 45
Apr 02, 2016: TherapeuticsMD Presents Detailed Results from Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy at ENDO 2016 46
Mar 24, 2016: Peptonic Medical receives approval for its clinical Phase 2b study 47
Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women’s Sexual Health Annual Meeting 48
Feb 18, 2016: TherapeuticsMD Announces Poster Presentations at International Society for the Study of Women’s Sexual Health Annual Meeting 48
Feb 10, 2016: Sermonix Pharmaceuticals to Give Two Lasofoxifene Presentations at International Society for the Study of Women's Sexual Health Meeting 49
Jan 05, 2016: DHEA Improves Vaginal Discomfort After Menopause 50
Dec 07, 2015: TherapeuticsMD Announces Positive Top-Line Results from its Phase 3 Rejoice Trial in Postmenopausal Women with Vulvar and Vaginal Atrophy Treated with 25 mcg, 10 mcg or 4 mcg of TX-004HR 51
Oct 07, 2015: Sermonix Receives Two Awards at the North American Menopause Society Annual Meeting 52
Appendix 53
Methodology 53
Coverage 53
Secondary Research 53
Primary Research 53
Expert Panel Validation 53
Contact Us 53
Disclaimer 54
List of Tables
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Late Stage Development, H1 2016 9
Comparative Analysis by Clinical Stage Development, H1 2016 10
Comparative Analysis by Early Stage Development, H1 2016 11
Products under Development by Companies, H1 2016 12
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by EndoCeutics, Inc., H1 2016 13
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Foamix Pharmaceuticals Ltd., H1 2016 14
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Ligand Pharmaceuticals, Inc., H1 2016 15
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by Mithra Pharmaceuticals S.A., H1 2016 16
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by PEPTONIC medical AB, H1 2016 17
Vaginal Atrophy (Atrophic Vaginitis) - Pipeline by TherapeuticsMD, Inc., H1 2016 18
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Stage and Target, H1 2016 21
Number of Products by Stage and Mechanism of Action, H1 2016 23
Number of Products by Stage and Route of Administration, H1 2016 25
Number of Products by Stage and Molecule Type, H1 2016 27
Vaginal Atrophy (Atrophic Vaginitis) Therapeutics - Recent Pipeline Updates, H1 2016 39
Vaginal Atrophy (Atrophic Vaginitis) - Dormant Projects, H1 2016 44
List of Figures
Number of Products under Development for Vaginal Atrophy (Atrophic Vaginitis), H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Assessment by Monotherapy Products, H1 2016 19
Number of Products by Targets, H1 2016 20
Number of Products by Stage and Targets, H1 2016 20
Number of Products by Mechanism of Actions, H1 2016 22
Number of Products by Stage and Mechanism of Actions, H1 2016 22
Number of Products by Routes of Administration, H1 2016 24
Number of Products by Stage and Routes of Administration, H1 2016 24
Number of Products by Molecule Types, H1 2016 26
Number of Products by Stage and Molecule Types, H1 2016 26
